Telaprevir: Clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions

Clinical Pharmacokinetics

Volumn 52, Issue 7, 2013, Pages 487-510

  Kiang, Tony K L ^a   Wilby, Kyle J ^b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Qatar University ^*  (Qatar)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ATAZANAVIR; ATORVASTATIN; BUPRENORPHINE; CYCLOSPORIN A; CYTOCHROME P450 3A4; DARUNAVIR PLUS RITONAVIR; DIGOXIN; EFAVIRENZ; ESCITALOPRAM; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; METHADONE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; NALOXONE; NORETHISTERONE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; TACROLIMUS; TELAPREVIR; TENOFOVIR; UNINDEXED DRUG; ZOLPIDEM;

ANEMIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HEPATITIS C; HUMAN; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; HUMANS; OLIGOPEPTIDES; PROTEASE INHIBITORS;

EID: 84879664119     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0053-x     Document Type: Review

References (54)

1. Williams R. Global challenges in liver disease. Hepatology. 2006;44:521-6.
2. Alzawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344-55.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
4. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 1997;26:122s-7s.
5. Klibanov OM, Williams SH, Smith LS, et al. Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy. 2011;31:951-74.
6. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-64.
7. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology. 2006;131:478-84.
8. Smith LS, Nelson M, Naik S, et al. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother. 2011;45:639-48.
9. Vertex Pharmaceuticals Incorporated. Telaprevir center for drug evaluation and research clinical pharmacology and biopharmaceutics review(s). 1-383. 2010 [online]. Available at URL: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/201917Orig1s000ClinPharmR.pdf [Accessed 2012 Oct 29].
10. Morikawa K, Lange CM, Gouttenoire J, et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat. 2011;18:305-15.
11. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2006;50:899-909.
12. Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother. 2006;50:1813-22.
13. Vertex Pharmaceuticals Incorporated. Incivek Product Monograph. 2012 [online]. Available from URL: http://pi.vrtx.com/files/canadapm-telaprevir-en. pdf [Accessed 2012 Oct 29].
14. Chakilam A, Chavan A, Smith G, et al. Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and warfarin. 2011. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy [online]. Available at URL: http://regist2.virology-education.com/2011/6HEPPK/docs/14-Garg.pdf [Accessed 2012 Oct 29].
15. Garg V, Kauffman RS, Beaumont M, et al. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther 2012; Sep 7. doi: 10.3851/IMP2356.
16. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1850.
17. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1303.
18. Jacobson I, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2416.
19. Sherman K, Flamm S, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1024.
20. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-28.
21. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011;140:459-68.
22. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131:997-1002.
23. Yamada I, Suzuki F, Kamiya N, et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat. 2012;19:112-9.
24. Forestier N, Reesink W, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007;46:640-8.
25. Adiwijaya B, Chandorkar G, van Heeswijk R, et al. The effect of mild and moderate hepatic impairment on telaprevir pharmacokinetics. 2011. 6th International Workshop on the Clinical Pharmacology of Hepatitis Therapy [online]. Available at URL: http://regist2.virology-education.com/2011/6HEPPK/ docs/05-Garg.pdf [Accessed 2012 Oct 29].
26. van Heeswijk R, Van de Voorde A, Boogaerts G, et al. The effect of severe renal impairment on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir. J Hepatol. 2011;54 Suppl 1:s492 (Abstract).
27. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008;49:163-9.
28. McHutchison JG, Everson GT, Gordon S, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-38.
29. Buti M, Agarwal K, Horsmans Y, et al. OPTIMIZE Trials: Noninferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV-infected patients. 63rd annual meeting of the American Association for the Study of Liver Diseases, Boston; 2012 (Abstract).
30. Kieffer T, De Meyer S, Bartels DJ, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE. 2012;7:1-12.
31. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767-77.
32. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-alpha-2a+RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. 19th conference on retroviruses and opportunistic infections, Seattle; 2012 (Abstract).
33. Adiwijaya BS, Kieffer TL, Henshaw J, et al. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol. 2012;8:e1002339.
34. Kempf DJ, Klein C, Chen H, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother. 2007;18:163-7.
35. Kunze A, Huwyler J, Camenisch G, et al. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012;84:1096-102.
36. Food and Drug Administration. FDA guidance for industry, drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations (draft guidance). 2012 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm292362.pdf [Accessed 2012 Oct 29].
37. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-80.
38. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20-7.
39. Lee JE, van Heeswijk R, Alves K, et al. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother. 2011;55:4569-74.
40. Garg V, Chandorkar G, Farmer HF, et al. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol. 2012;52:1566-73.
41. Luo X, van Heeswijk R, Alves K, et al. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers. 2011. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy [online]. Available from URL: http://regist2.virology-education.com/2011/6HEPPK/docs/08- Garg.pdf [Accessed 2012 Oct 29].
42. van Heeswijk R, Boogaerts G, De Paepe E, et al. The pharmacokinetic (PK) interaction between escitalopram and the investigational HCV protease inhibitor telaprevir. 5th international workshop on clinical pharmacology of hepatitis therapy, Boston; 2010 (Abstract).
43. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46:281-90.
44. Luo X, Trevejo J, van Heeswijk R, et al. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother. 2012;56:3641-7.
45. van Heeswijk R, Vandevoorde A, Verboven P, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. 46th annual meeting of the european association for the study of the liver, Berlin; 2011 (Abstract).
46. Garg V, van Heeswijk R, Yang Y, et al. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol. 2012;52:1574-83.
47. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol. 2012;75:431-9. doi: 10.1111/j.1365-2125.2012.04345.x.
48. van Heeswijk R, Boogaerts G, De Paepe E, et al. The pharmacokinetic (PK) interaction between esomeprazole and the investigational HCV protease inhibitor telaprevir. 5th international workshop on clinical pharmacology of hepatitis therapy, Boston; 2010 (Abstract).
49. Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochrome P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40:1698-711.
50. Garg V, Luo X, McNair L, et al. The effect of low-dose ritonavir on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers. The 18th conference on retroviruses and opportunistic infections, Boston; 2011 (Abstract).
51. van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between antiretroviral agents and the investigational HCV protease inhibitor telaprevir in healthy volunteers. 18th conference on retroviruses and opportunistic infections, Boston; 2011 (Abstract).
52. Kakuda T, Leopold L, Nijs S. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomized, two-way crossover trial. 13th international workshop on clinical pharmacology of HIV therapy, Barcelona; 2012 (Abstract).
53. van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th conference on retroviruses and opportunistic infections, Boston; 2011 (Abstract).
54. van Heeswijk R, Garg V, Boogaerts G, Vandebosch A, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51th ICAAC meeting, Chicago; 2011 (Abstract).